Researchers have discovered biomarkers that predict which patients with advanced non-small cell lung cancer will respond to a combination treatment of the anti-inflammatory drug Celebrex and the growth factor receptor blocker Tarceva. The findings may help oncologists personalize treatment, prescribing drugs they know patients will respond to and sparing them from therapies that won't work. Both drugs are taken in pill form once a day and result in fewer side effects than conventional treatments such as chemotherapy.



Recent comments
29 weeks 4 days ago